Peter Wolpert, Chairman of the Board since 2019 of Moberg Pharma AB (publ), has informed the Nomination Committee that he has been appointed CEO of Industrifonden starting from March 2022. Peter will complete his current term as chairman of the board but will not be available for reelection at the Annual General Meeting in May 2022. Peter Wolpert has been CEO of Moberg Pharma since 2006 and became Chairman of the Board in 2019 in connection with the divestment of Moberg's commercial OTC operations.